蛋白氨酸酸酶:癌症治疗耐药性的新兴作用
Min Zhao1, Wen Shuai1, Zehao Su1,2
1Innovation Center of Nursing Research, Nursing Key Laboratory of Sichuan Province, Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, National Clinical Research Center for Geriatrics, West China Hospital, West China School of Nursing, Sichuan University, Chengdu, Sichuan, P. R. China.
Cancer communications (London, England)
|May 14, 2024
概括
蛋白氨酸酸酶 (PTPs) 通过调节信号通路来驱动癌症治疗耐药性. 在组合治疗中抑制PTP可能会克服耐药性并促进瘤回归,临床试验正在进行中.
科学领域:
- 分子生物学分子生物学
- 癌症生物学 癌症生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 氨酸酸化调节细胞信号传递,蛋白氨酸酸酶 (PTPs) 调解脱化和通路交叉通话.
- 通过PTP介导的途径在癌症中起到信号枢纽的作用,使细胞能够通过激活生长途径或抑制免疫微环境来抵抗治疗.
- PTPs与癌症药物耐药性有关,导致治疗失败.
研究的目的:
- 对针对性治疗和免疫检查点疗法的耐药性中PTP介导途径的最新发现进行审查.
- 突出PTPs在癌细胞存活和治疗逃避中的作用.
主要方法:
- 临床前和临床研究的文献综述.
- 对PTP参与抵抗机制的分析.
- 综合PTP抑制作为治疗策略的证据.
主要成果:
- PTPs对于开发对向治疗和免疫检查点治疗的耐药性至关重要.
- 抑制PTP可以逆转耐药性并提高抗癌药物的疗效.
- PTPs调节瘤微环境,并在治疗压力下促进癌细胞存活.
结论:
- 抑制PTP是一种对抗癌症联合治疗的有希望的策略.
- 将PTP抑制剂与现有治疗相结合,可以实现长期的瘤回归.
- 临床试验正在评估PTP抑制在晚期癌症中的安全性和有效性.
相关概念视频
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Protein Kinases and Phosphatases
13.1K
Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
13.1K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K


